Structured Early detection of Asymptomatic Liver Cirrhosis: Results of the population-based liver screening program SEAL
- PMID: 35472313
- DOI: 10.1016/j.jhep.2022.04.009
Structured Early detection of Asymptomatic Liver Cirrhosis: Results of the population-based liver screening program SEAL
Abstract
Background & aims: Detection of patients with early cirrhosis is of importance to prevent the occurrence of complications and improve prognosis. The SEAL program aimed at evaluating the usefulness of a structured screening procedure to detect cirrhosis as early as possible.
Methods: SEAL was a prospective cohort study with a control cohort from routine care data. Individuals participating in the general German health check-up after the age of 35 ("Check-up 35") at their primary care physicians were offered a questionnaire, liver function tests (aspartate and alanine aminotransferase [AST and ALT]), and follow-up. If AST/ALT levels were elevated, the AST-to-platelet ratio index (APRI) score was calculated, and patients with a score >0.5 were referred to a liver expert in secondary and/or tertiary care.
Results: A total of 11,859 participants were enrolled and available for final analysis. The control group comprised 349,570 participants of the regular Check-up 35. SEAL detected 488 individuals with elevated APRI scores (4.12%) and 45 incident cases of advanced fibrosis/cirrhosis. The standardized incidence of advanced fibrosis/cirrhosis in the screening program was slightly higher than in controls (3.83‰ vs. 3.36‰). The comparison of the chance of fibrosis/cirrhosis diagnosis in SEAL vs. in standard care was inconclusive (marginal odds ratio 1.141, one-sided 95% CI 0.801, +Inf). Of note, when patients with decompensated cirrhosis at initial diagnosis were excluded from both cohorts in a post hoc analysis, SEAL was associated with a 59% higher chance of early cirrhosis detection on average than routine care (marginal odds ratio 1.590, one-sided 95% CI 1.080, +Inf; SEAL 3.51‰, controls: 2.21‰).
Conclusions: The implementation of a structured screening program may increase the early detection rate of cirrhosis in the general population. In this context, the SEAL pathway represents a feasible and potentially cost-effective screening program.
Registration: DRKS00013460 LAY SUMMARY: Detection of patients with early liver cirrhosis is of importance to prevent the occurrence of complications and improve prognosis. This study demonstrates that the implementation of a structured screening program using easily obtainable measures of liver function may increase the early detection rate of cirrhosis in the general population. In this context, the 'SEAL' pathway represents a feasible and potentially cost-effective screening program.
Keywords: cirrhosis; liver fibrosis; non-invasive test; screening.
Copyright © 2022 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
Conflict of interest statement
Conflict of interest The authors disclose no potential financial or non-financial conflict of interests regarding this study. Please refer to the accompanying ICMJE disclosure forms for further details.
Comment in
-
Signed, SEALed, detected I'm your patient with advanced fibrosis or cirrhosis!J Hepatol. 2022 Sep;77(3):591-592. doi: 10.1016/j.jhep.2022.06.008. Epub 2022 Jun 20. J Hepatol. 2022. PMID: 35738506 No abstract available.
-
An individualized cirrhosis screening strategy might be more cost-effective in the general population.J Hepatol. 2022 Dec;77(6):1728-1729. doi: 10.1016/j.jhep.2022.06.035. Epub 2022 Jul 16. J Hepatol. 2022. PMID: 35843376 No abstract available.
-
SEAL: Why was this approach not effective?J Hepatol. 2023 Jan;78(1):e26-e27. doi: 10.1016/j.jhep.2022.07.031. Epub 2022 Aug 17. J Hepatol. 2023. PMID: 35985544 No abstract available.
-
Reply to: "An individualized cirrhosis screening strategy might be more cost-effective in the general population".J Hepatol. 2022 Dec;77(6):1730. doi: 10.1016/j.jhep.2022.08.006. Epub 2022 Aug 19. J Hepatol. 2022. PMID: 35988687 No abstract available.
Similar articles
-
Screening for liver fibrosis: lessons from colorectal and lung cancer screening.Nat Rev Gastroenterol Hepatol. 2024 Jul;21(7):517-527. doi: 10.1038/s41575-024-00907-2. Epub 2024 Mar 13. Nat Rev Gastroenterol Hepatol. 2024. PMID: 38480849 Review.
-
Population screening for cirrhosis.Hepatol Commun. 2024 Aug 26;8(9):e0512. doi: 10.1097/HC9.0000000000000512. eCollection 2024 Sep 1. Hepatol Commun. 2024. PMID: 39185917 Free PMC article. Review.
-
Costs of a structured early detection program for advanced liver fibrosis and cirrhosis: insights on the "plus" of Check-up 35.Z Gastroenterol. 2023 Oct;61(10):1371-1381. doi: 10.1055/a-1989-1971. Epub 2023 Jan 9. Z Gastroenterol. 2023. PMID: 36623821 English.
-
Association of genetic polymorphism -670A>G in the Fas gene and serum markers AST platelet ratio index, AST/ALT with significant fibrosis and cirrhosis in chronic hepatitis C.Genet Test Mol Biomarkers. 2012 Jun;16(6):531-5. doi: 10.1089/gtmb.2011.0098. Epub 2012 Feb 21. Genet Test Mol Biomarkers. 2012. PMID: 22352690
-
Role of AST to platelet ratio index in the detection of liver fibrosis in patients with recurrent hepatitis C after liver transplantation.J Gastroenterol Hepatol. 2007 Nov;22(11):1904-8. doi: 10.1111/j.1440-1746.2006.04628.x. J Gastroenterol Hepatol. 2007. PMID: 17914968
Cited by
-
FIB-4 and APRI for cirrhosis detection in a privately insured national cohort.JHEP Rep. 2023 Sep 30;6(1):100925. doi: 10.1016/j.jhepr.2023.100925. eCollection 2024 Jan. JHEP Rep. 2023. PMID: 38074510 Free PMC article.
-
Screening patients in general practice for advanced chronic liver disease using an innovative IT solution: The Liver Toolkit.Hepatol Commun. 2024 Jun 27;8(7):e0482. doi: 10.1097/HC9.0000000000000482. eCollection 2024 Jul 1. Hepatol Commun. 2024. PMID: 38934697 Free PMC article.
-
Screening for liver fibrosis: lessons from colorectal and lung cancer screening.Nat Rev Gastroenterol Hepatol. 2024 Jul;21(7):517-527. doi: 10.1038/s41575-024-00907-2. Epub 2024 Mar 13. Nat Rev Gastroenterol Hepatol. 2024. PMID: 38480849 Review.
-
Predictive value of blood coagulation and routine blood indices for rebleeding after endoscopic treatment in hepatitis B-related cirrhotic patients with esophagogastric fundal varices: a logistic regression model analysis.Am J Transl Res. 2024 Jul 15;16(7):2982-2994. doi: 10.62347/ICQU1086. eCollection 2024. Am J Transl Res. 2024. PMID: 39114728 Free PMC article.
-
Population screening for cirrhosis.Hepatol Commun. 2024 Aug 26;8(9):e0512. doi: 10.1097/HC9.0000000000000512. eCollection 2024 Sep 1. Hepatol Commun. 2024. PMID: 39185917 Free PMC article. Review.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical